{"id":25118,"date":"2022-10-14T12:48:00","date_gmt":"2022-10-14T04:48:00","guid":{"rendered":"https:\/\/flcube.com\/?p=25118"},"modified":"2025-02-03T12:55:44","modified_gmt":"2025-02-03T04:55:44","slug":"ausper-biopharma-raises-usd-16m-for-hbv-drug-and-vaccine-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25118","title":{"rendered":"Ausper Biopharma Raises USD 16M for HBV Drug and Vaccine Development"},"content":{"rendered":"\n

Ausper Biopharma, Inc, a developer of drugs and vaccines for chronic hepatitis B virus (HBV) based in Hangzhou, has reportedly raised USD 16 million in a Pre-Series A financing round. The round was backed by InnoPinnacle Fund and angel investors. The proceeds will be used to advance global clinical studies for its small nucleic acid drugs aimed at curing HBV and to develop other pipelines.<\/p>\n\n\n\n

Company Background and Platforms<\/strong>
Founded in 2019, Ausper Bio is known for its small nucleic acid drug platform for curing hepatitis B, therapeutic vaccine platform for hepatitis B, and a jointly developed nasal spray antibody platform, all of which are at the clinical filing stages. Current treatments for chronic HBV mainly include nucleoside analogues and interferon, which rarely achieve a functional cure. Ausper Bio’s small nucleic acid drugs can act on the mRNA of the hepatitis B virus through RNA interference technology, destroy its function as a post-transcriptional translation template, and prevent the synthesis of relevant viral proteins, thereby inhibiting the formation of viral particles.<\/p>\n\n\n\n

Future Outlook<\/strong>
The Pre-Series A financing round underscores Ausper Biopharma’s commitment to advancing innovative treatments for chronic hepatitis B. By leveraging RNA interference technology, Ausper Bio aims to address significant unmet medical needs and improve outcomes for patients with chronic HBV.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Ausper Biopharma, Inc, a developer of drugs and vaccines for chronic hepatitis B virus (HBV)…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[119,30,20,64,89],"class_list":["post-25118","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ausperbio","tag-biotech","tag-finance","tag-rnai-aso","tag-viral-hepatitis"],"yoast_head":"\nAusper Biopharma Raises USD 16M for HBV Drug and Vaccine Development - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ausper Biopharma, Inc, a developer of drugs and vaccines for chronic hepatitis B virus (HBV) based in Hangzhou, has reportedly raised USD 16 million in a Pre-Series A financing round. The round was backed by InnoPinnacle Fund and angel investors. The proceeds will be used to advance global clinical studies for its small nucleic acid drugs aimed at curing HBV and to develop other pipelines.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25118\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ausper Biopharma Raises USD 16M for HBV Drug and Vaccine Development\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25118\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-14T04:48:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-03T04:55:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25118#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25118\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ausper Biopharma Raises USD 16M for HBV Drug and Vaccine Development\",\"datePublished\":\"2022-10-14T04:48:00+00:00\",\"dateModified\":\"2025-02-03T04:55:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25118\"},\"wordCount\":226,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AusperBio\",\"Biotech\",\"Finance\",\"RNAi \\\/ ASO\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25118#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25118\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25118\",\"name\":\"Ausper Biopharma Raises USD 16M for HBV Drug and Vaccine Development - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-10-14T04:48:00+00:00\",\"dateModified\":\"2025-02-03T04:55:44+00:00\",\"description\":\"Ausper Biopharma, Inc, a developer of drugs and vaccines for chronic hepatitis B virus (HBV) based in Hangzhou, has reportedly raised USD 16 million in a Pre-Series A financing round. The round was backed by InnoPinnacle Fund and angel investors. The proceeds will be used to advance global clinical studies for its small nucleic acid drugs aimed at curing HBV and to develop other pipelines.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25118#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25118\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25118#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ausper Biopharma Raises USD 16M for HBV Drug and Vaccine Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ausper Biopharma Raises USD 16M for HBV Drug and Vaccine Development - Insight, China's Pharmaceutical Industry","description":"Ausper Biopharma, Inc, a developer of drugs and vaccines for chronic hepatitis B virus (HBV) based in Hangzhou, has reportedly raised USD 16 million in a Pre-Series A financing round. The round was backed by InnoPinnacle Fund and angel investors. The proceeds will be used to advance global clinical studies for its small nucleic acid drugs aimed at curing HBV and to develop other pipelines.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25118","og_locale":"en_US","og_type":"article","og_title":"Ausper Biopharma Raises USD 16M for HBV Drug and Vaccine Development","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=25118","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-10-14T04:48:00+00:00","article_modified_time":"2025-02-03T04:55:44+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25118#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25118"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ausper Biopharma Raises USD 16M for HBV Drug and Vaccine Development","datePublished":"2022-10-14T04:48:00+00:00","dateModified":"2025-02-03T04:55:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25118"},"wordCount":226,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AusperBio","Biotech","Finance","RNAi \/ ASO","Viral hepatitis"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25118#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25118","url":"https:\/\/flcube.com\/?p=25118","name":"Ausper Biopharma Raises USD 16M for HBV Drug and Vaccine Development - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-10-14T04:48:00+00:00","dateModified":"2025-02-03T04:55:44+00:00","description":"Ausper Biopharma, Inc, a developer of drugs and vaccines for chronic hepatitis B virus (HBV) based in Hangzhou, has reportedly raised USD 16 million in a Pre-Series A financing round. The round was backed by InnoPinnacle Fund and angel investors. The proceeds will be used to advance global clinical studies for its small nucleic acid drugs aimed at curing HBV and to develop other pipelines.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25118#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25118"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25118#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ausper Biopharma Raises USD 16M for HBV Drug and Vaccine Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25118"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25118\/revisions"}],"predecessor-version":[{"id":25119,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25118\/revisions\/25119"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}